AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Wesfarmers’ (WES) core retail strength drives consistent revenue.
- Healthcare and lithium investments signal long-term diversification.
- Robust capital allocation keeps return metrics attractive.
Wesfarmers (ASX:WES) is one of Australia’s most recognisable conglomerates, and its performance continues to draw attention. With its share price edging near record highs and a valuation higher than the market average, some might question if it’s still a compelling opportunity. But when looking beyond the surface, there are a few strategic pillars that could justify a closer look at this ASX 200 stock.
Strong Retail Foundation
The bulk of Wesfarmers’ revenue – approximately 76% in FY24 – comes from its retail divisions: Bunnings, Kmart, and Officeworks. These brands are embedded in Australian households and continue to perform well despite wider economic pressures. Bunnings’ dominance in the hardware space, for instance, is exemplified by its significant market share and brand trust among DIY enthusiasts.
The consistency and relevance of these businesses across different consumer segments position Wesfarmers to weather varied market conditions. These divisions also benefit from economies of scale and operational efficiencies, which support consistent earnings.
Strategic Capital Allocation
Wesfarmers has demonstrated disciplined and effective capital management over the years. A standout example is the acquisition and eventual demerger of Coles Group (ASX:COL), which helped unlock significant value. Rather than pursuing frequent share dilutions, Wesfarmers has preserved shareholder value with minimal changes to its share count since 2009.
This approach has helped the company maintain a robust return on equity – 31.2% in the first half of FY24 – while also ensuring steady dividend growth. The strategy reflects a commitment to long-term value creation rather than short-term market gains.
Growth Through Diversification
Beyond retail, Wesfarmers is branching into high-potential sectors. Its acquisition of Australian Pharmaceutical Industries in 2022 laid the foundation for a new health division. The company now operates Priceline pharmacy stores, skincare clinics, and wholesale pharmaceutical distribution. These initiatives are designed to modernise the customer experience and enhance supply chain efficiency.
On the energy front, Wesfarmers is invested in lithium through the Mt Holland mine and Kwinana refinery. Although its lithium segment has incurred losses, the venture supports the broader energy and chemicals division and positions the company for future upside in global electrification trends.
Wesfarmers may not appear inexpensive with a P/E ratio of 37x, but its ability to consistently generate high returns, expand into new sectors, and maintain a strong capital framework suggests there may be more value beneath the surface. For investors seeking a diversified ASX200 play with exposure to retail, healthcare, and future-facing resources, Wesfarmers (WES) presents a unique blend of resilience and optionality.
